17.05.2010 • NewsAstellasOSIMergers & Acquisitions (M&A)

Astellas CEO Says Seeks to Buy 90% Of OSI Shares

Astellas Pharma, Japan's No.2 drugmaker, seeks to buy at least 90% of shares in U.S. drugmaker OSI Pharmaceuticals with its tender offer, the company's chief executive said on Monday.

"As for how many shares we may obtain, we will carry out the tender offer, targeting 90% or more," Astellas president Masafumi Nogimori told a news conference.

Astellas, Japan's No.2 drugmaker, agreed to buy the U.S. biotech for $4 billion in cash in a sweetened bid that allows it to add OSI's blockbuster cancer drug Tarceva to its line-up.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.